Advertisement
Canada markets open in 5 hours 2 minutes
  • S&P/TSX

    21,714.54
    -297.08 (-1.35%)
     
  • S&P 500

    5,035.69
    -80.48 (-1.57%)
     
  • DOW

    37,815.92
    -570.17 (-1.49%)
     
  • CAD/USD

    0.7263
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    80.94
    -0.99 (-1.21%)
     
  • Bitcoin CAD

    78,545.92
    -8,022.46 (-9.27%)
     
  • CMC Crypto 200

    1,231.65
    -107.42 (-8.03%)
     
  • GOLD FUTURES

    2,294.80
    -8.10 (-0.35%)
     
  • RUSSELL 2000

    1,973.91
    -42.12 (-2.09%)
     
  • 10-Yr Bond

    4.6860
    +0.0720 (+1.56%)
     
  • NASDAQ futures

    17,475.75
    -95.50 (-0.54%)
     
  • VOLATILITY

    15.82
    +0.17 (+1.09%)
     
  • FTSE

    8,174.29
    +30.16 (+0.37%)
     
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • CAD/EUR

    0.6805
    +0.0003 (+0.04%)
     

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

SOMERSET, N.J., April 11, 2024--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.

During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.

Investors and other interested parties may join the live audio webcast of the call via this weblink.

A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes.

ADVERTISEMENT

ABOUT LEGEND BIOTECH

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411972035/en/

Contacts

INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com

PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com